Efficacy and safety of Rituximab infusion in pemphigus patients: A retrospective study

This is a retrospective study to assess the efficacy and safety of Rituximab infusion in pemphigus patients in our institute based on the records available in the department register. Rituximab was FDA approved in 2018 for the treatment of moderate to severe pemphigus vulgaris and it has been increasingly used and has revolutionized the treatment of immunobullous diseases resulting in the major shift of focus from more global immunosuppression to targeted immunotherapy. This study purpose is to provide critical analysis of use of rituximab in the treatment of pemphigus patients.